Trump Unveils Bombshell Vaccine Shift That Has Experts Alarmed

• READ MORE: RFK Jr.'s surprising shift on MMR vaccine following measles outbreak

The Trump administration has unveiled two significant vaccine strategies in an attempt to enhance security and decrease the amount of inoculations administered to Americans .

The Department of Health and Human Services (HHS) has decided that all newly developed vaccines must undergo placebo-controlled trials prior to receiving approval for usage.

This indicates that within the study, certain participants will be administered the vaccine whereas others will be given an innocuous substance like saline prior to comparing the outcomes.

Robert F Kennedy, who heads HHS, stated that this step will enhance public confidence in vaccinations and improve openness. However, certain specialists worry it might result in unscrupulous conduct.

Although vaccines for emerging illnesses frequently undergo testing using placebos, such methods aren’t employed when developing injections for well-known, treatable infections like those caused by the measles and polio viruses. Professionals argue that intentionally subjecting unvaccinated individuals to an avoidable disease is morally wrong.

Meanwhile, the HHS also announced the creation of a new $500 million project developing vaccines that protect against multiple strains of viruses in a single dose.

The ‘universal’ vaccines , expected to gain FDA approval by 2029 at the earliest, aims to decrease the necessity for annual booster shots against diseases such as Covid.

The latest initiative is consistent with Kennedy’s previous statements suggesting that 'No other nation administers as many vaccinations to children within their first year as the United States' and 'We are administering numerous vaccines to kids, many of which may be unnecessary.'

The platform will receive support from the US government’s Biomedical Advanced Research and Development Authority (BARDA) and the National Institutes of Health (NIH), with no participation from the private sector whatsoever.

RFK Jr has often accused government health agencies of conspiring with Big Pharma to create profitable drugs that serve no real necessity, and vowed upon assuming office, to curtail the industry's participation in governmental programs focused on health and scientific research, like vaccine creation.

The initial phase of the project will concentrate on developing a vaccine for all strains of influenza. and Covid vaccines , focusing on two particular vaccines: the BPL-1357 influenza shot, which is presently waiting for Phase 2 trials, and the universal BPL-24910 coronavirus vaccine, set to commence Phase 1 trials shortly.

The development of a universal vaccine is being led by two newly appointed senior scientists at the NIH, Drs Matthew Memolo and Jeffrey Taubenberger.

A vaccine that protects against all coronaviruses or influenza viruses could substantially decrease the required vaccinations. when contrasted with present vaccination approaches .

Although individuals typically receive an annual flu vaccination, the allure of a universal vaccine lies in its potential to provide prolonged immunity against multiple strains, thereby eliminating the necessity for yearly shots.

Additionally, people generally need two doses of a Covid vaccine and regularly boosters every year.

A universal Covid vaccine would replace those boosters with one shot roughly every five years - preventing individuals from getting poked an extra 15 times over ten years .

The technology supporting these universal vaccines relies on the BPL platform, which uses chemical processes to deactivate entire viruses while keeping various viral proteins intact (unlike only one protein, such as the spike protein found in COVID-19).

These vaccines are probably more secure for people with weakened immune systems compared to live-attenuated vaccines since they do not multiply or lead to an infection.

By maintaining several viral proteins, these vaccines might elicit stronger T-cell reactions than subunit or mRNA vaccines, potentially providing wider and longer-lasting immunity.

As per HHS, the vaccine technology 'is entirely owned by the government and developed by NIH.'

'This method guarantees complete openness, civic oversight, and independence from business-related biases.'

In pursuit of offering complete transparency to the public, an HHS representative stated that mandating all new vaccines to go through placebo-controlled trials – where one group receives a shot without the vaccine – represents ‘a significant shift from previous procedures.’

Many vaccines have been evaluated using this method, however, specialists contend that it is not effective—and could potentially be immoral—when applied to long-standing vaccines such as measles and polio. Denying these individuals with an approved safeguard by placing them in the placebo group might expose them to the avoidable threat of contracting a fatal disease.

RFK Jr is not the initial public health authority to advocate for the creation of a universal influenza vaccine. For around 15 years, the National Institutes of Health (NIH) have supported initiatives aimed at developing such a vaccine, with one project led by Dr Taubenberger laying down crucial technological foundations. Nonetheless, achieving this objective continues to be challenging.

The HHS statement about the new initiative indicates that clinical trials for a universal flu vaccine will not start for at least an additional year, with the earliest possible approval for both universal flu and Covid vaccines expected by 2029.

The timeline is significantly longer than that of the remarkably efficient COVID-19 vaccines produced by major pharmaceutical companies like Pfizer, Moderna, and Johnson & Johnson. These vaccines commenced development in 2020 and received approval from the FDA as safe and efficacious by December of the same year.

RFK Jr previously made the erroneous assertion that this accelerated schedule entailed compromising thorough safety tests.

The steps during the safety trials were not omitted but conducted concurrently. The trial phases operated simultaneously as scientists continually examined the data.

The project progressed more swiftly due to unrestricted financing, worldwide enrollment of tens of thousands of participants, and instantaneous data evaluation free from cumbersome administrative formalities.

The most recent version of the Gold Standard platform will be brought into closer alignment with the conventional timeline for vaccine development.

Preclinical studies along with Phase 1 trials typically last around two years, whereas subsequent phases from two to four might extend for as long as four years.

However, once universal vaccines become available, tens of thousands of lives could potentially be saved. In 2019, US-based scientists from leading institutions calculated that a broad-spectrum flu vaccine would prevent 5.3 million infections , approximately 81,000 hospitalizations, and about 6,300 fatalities from influenza occur annually in the US.

This might save the U.S. healthcare system approximately $1.1 billion each year when compared to the period before Covid-19 flu seasons.

Dr Jay Bhattacharya, director of NIH, stated: "Generation Gold Standard represents a significant change in approach."

‘It extends vaccine protection beyond strain-specific limits and prepares for flu viral threats – not just today’s, but tomorrow’s as well – using traditional vaccine technology brought into the 21st century.’

This significant funding comes amid an extensive effort across all governmental levels aimed at reducing expenditures. More than 800 research grants from the NIH have been revoked. It’s anticipated that approximately 20,000 staff members from HHS have lost their jobs, with about 1,200 being NIH scientists.

Read more